Worldwide Patented Phase III Ready Rx Injectable for Inoperable Tumors AND Topical Application for Melanoma with Skin Resuscitation Factor® (SRF®)
SRF® (Skin Resuscitation Factor®)
- SRF® Increases the synthesis of Nitric Oxide at Tumor Sites that is needed to kill tumors
- SRF® Reduces Hypoxemia at Tumor sites, making Tumors more susceptible to destruction by cancer drugs, while protecting normal cells
- In both Tissue Culture Studies and in Numerous Human Clinical Trials, for both the Topical and Injectable version.
- SRF® enhanced the Killing and Shrinkage of Tumors in 11 Patients with Various Cancers and all Eleven were still Cancer Free after 5 years
- SRF Reduced the Side Effects of Cancer Drugs
- SRF Enhances the Effect of Cancer Drugs and Immuno-stimulators
Manufactured in the United States
Worldwide Patents and New Drug Patents Pending – Phase III Ready